Login to Your Account

Cardiome's Heart Therapy Misses Phase II Endpoints

By Randall Osborne

Tuesday, August 16, 2005
Cardiome Pharma Corp.'s oxypurinol fizzled in top-line results from a Phase II trial against congestive heart failure, missing the primary and secondary endpoints, but officials will sift the data further before making a decision on the fate of the program. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription